Alcohol and Food Misuse Lead to Fatty Liver Diseases
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2238
Special Issue Editors
Interests: alcoholic liver disease; non-alcoholic liver disease; intestinal microbiome; hepatitis C; COVID-19
Interests: alcoholic liver disease; non-alcoholic steatohepatitis; hepatocytotoxicity; inflammatory biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The liver has a unique blood supply from both portal and systemic sources. Portal blood is delivered to the liver directly via absorption from the GI tract. This includes both substances that are ingested and also substances that are either produced or metabolized by the intestinal microbiome.
Hepatic steatosis is a result of either alcohol ingestion or changes in hepatic metabolism linked to metabolic syndrome, including endogenous alcohol production. Steatosis may progress via steatohepatitis, fibrosis and cirrhosis and its complication include hepatocellular carcinoma.
As a result of the worldwide epidemic of obesity, metabolic-associated fatty liver disease (MAFLD) is very common with a prevalence of more than 30% in developed countries. Alcohol use has also increased, linked to the COVID-19 pandemic. The combination of these 2 drivers has had a major effect on alcoholic and metabolic-associated fatty liver disease.
It is the aim of this special edition to review the pathogenesis of hepatic steatosis, the clinical features, diagnosis and management of these two disorders. We will explore both the common mechanistic systems and the involvement of the microbiome.
Dr. Stephen D.H. Malnick
Prof. Dr. Neuman Manuela
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolic associated fatty liver disease - MAFLD
- alcoholic liver disease
- non-alcoholic steatohepatitis
- alcohol and COVID
- cytokine storm
- microbiome
